Gntb-A, a Novel Sh2d1a-Associated Surface Molecule Contributing to the Inability of Natural Killer Cells to Kill Epstein-Barr Virus–Infected B Cells in X-Linked Lymphoproliferative Disease by Bottino, Cristina et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2001/08/235/12 $5.00
Volume 194, Number 3, August 6, 2001 235–246
http://www.jem.org/cgi/content/full/194/3/235
 
235
 
NTB-A, a Novel SH2D1A-associated Surface Molecule 
Contributing to the Inability of Natural Killer Cells to 
Kill Epstein-Barr Virus–infected B Cells in 
X-linked Lymphoproliferative Disease
 
Cristina Bottino,
 
1
 
 Michela Falco,
 
2
 
 Silvia Parolini,
 
3
 
Emanuela Marcenaro,
 
2
 
 Raffaella Augugliaro,
 
1
 
 Simona Sivori,
 
2
 
Elena Landi,
 
2
 
 Roberto Biassoni,
 
1
 
 Luigi D. Notarangelo,
 
4
 
Lorenzo Moretta,
 
2, 5
 
 and Alessandro Moretta
 
2
 
1
 
Istituto Nazionale per la Ricerca sul Cancro, 16132 Genova, Italy
 
2
 
Dipartimento di Medicina Sperimentale, Università di Genova, 16132 Italy
 
3
 
Dipartimento di Scienze Biomediche e Biotecnologie and 
 
4
 
Istituto di Medicina Molecolare Angelo 
Nocivelli, Clinica Pediatrica, Università di Brescia, Brescia 25123 Italy
 
5
 
Istituto Giannina Gaslini, 16148 Genova, Italy
 
Abstract
 
In humans, natural killer (NK) cell function is regulated by a series of receptors and coreceptors
with either triggering or inhibitory activity. Here we describe a novel 60-kD glycoprotein,
termed NTB-A, that is expressed by all human NK, T, and B lymphocytes. Monoclonal anti-
body (mAb)-mediated cross-linking of NTB-A results in the induction of NK-mediated cytotox-
icity. Similar to 2B4 (CD244) functioning as a coreceptor in the NK cell activation, NTB-A also
triggers cytolytic activity only in NK cells expressing high surface densities of natural cytotoxicity
receptors. This suggests that also NTB-A may function as a coreceptor in the process of NK cell
activation. Molecular cloning of the cDNA coding for NTB-A molecule revealed a novel mem-
ber of the immunoglobulin superfamily belonging to the CD2 subfamily. NTB-A is character-
ized, in its extracellular portion, by a distal V-type and a proximal C2-type domain and by a
cytoplasmic portion containing three tyrosine-based motifs. NTB-A undergoes tyrosine phos-
phorylation and associates with the Src homology 2 domain–containing protein (SH2D1A) as
well as with SH2 domain–containing phosphatases (SHPs). Importantly, analysis of NK cells de-
rived from patients with X-linked lymphoproliferative disease (XLP) showed that the lack of
SH2D1A protein profoundly affects the function not only of 2B4 but also of NTB-A. Thus, in
XLP-NK cells, NTB-A mediates inhibitory rather than activating signals. These inhibitory signals
are induced by the interaction of NTB-A with still undefined ligands expressed on Epstein-Barr
 
virus (EBV)-infected
 
 
 
target cells. Moreover, mAb-mediated masking of NTB-A can partially re-
vert this inhibitory effect while a maximal recovery of target cell lysis can be obtained when both
2B4 and NTB-A are simultaneously masked. Thus, the altered function of NTB-A appears to
play an important role in the inability of XLP-NK cells to kill EBV-infected
 
 
 
target cells.
Key words: X-linked lymphoproliferative disease • coreceptors function • natural killer cells • 
Epstein-Barr virus • Src homology 2 domain–containing protein
 
Introduction
 
Important advances have recently been made in our under-
standing of the role of human NK cells in host defenses.
Progress is mainly consequent to the discovery of a series of
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receptors, expressed at the NK cell surface, regulating NK
cell functions. Some of these receptors inhibit NK cells by
monitoring the expression of MHC class I molecules on
normal cells (1–3). Other receptors are responsible for NK
cell activation (4). This occurs when NK cells interact with
cells that, as a consequence of viral infection or tumor trans-
formation, do not express, or express inadequate amounts of,
MHC class I molecules (5). In humans, different triggering 
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receptors have been identified. NKp46 (6, 7), NKp30 (8),
and NKp44 (9, 10), collectively termed “natural cytotoxicity
receptors” (NCRs)
 
*
 
 (11) are selectively expressed by NK
cells and cooperate with each other in the induction of natu-
ral cytotoxicity. NCRs are characterized by a coordinated
surface expression and a direct correlation exists between
their surface density and the ability of NK cells to kill various
tumors (12). NCRs are all members of the Ig superfamily
(IG-SF), display low degree of similarity to each other, and
are coupled to different signal transducing adaptor proteins
including CD3
 
 
 
, Fc
 
 
 
RI
 
 
 
, and KARAP/DAP12 (8–10).
Another triggering receptor expressed by NK cells is
represented by NKG2D, a C-type lectin surface molecule
encoded within the “NK gene complex” on human chro-
mosome 12 (13). Upon recognition of the stress-inducible
MICA/B molecules (14) on target cells, NKG2D strongly
enhances the NK-mediated cytotoxicity (14, 15). Different
from NCR, NKG2D is also expressed by virtually all
TCR-
 
 
 
/
 
 
 
 
 
 as well as by CD8
 
 
 
 TCR-
 
 
 
/
 
 
 
 
 
 cells. Its func-
tion requires the association with a newly identified signal-
ing subunit termed DAP10 (16) or KAP10 (17). As re-
cently shown, NKG2D can complement the role of NCRs
in tumor cell lysis, their relative involvement being prima-
rily dependent on the type of target and/or effector cells
analyzed (15).
Notably, optimal NK cell triggering may require the
function of another molecule termed 2B4 (CD244; refer-
ences 18–20). This molecule is expressed not only by NK
cells, but also by monocytes and a subset of CD8
 
 
 
 T cells.
In NK cells, the mAb-mediated cross-linking of 2B4 or its
engagement by CD48 (i.e., the 2B4 ligand) results in the
enhancement of cytolytic activity (18–22). Analysis at the
clonal level has clearly shown that this effect is restricted to
NK cells expressing high NCR surface density (NCR
 
bright
 
).
Moreover, mAb-mediated modulation of NCRs results in
NK cell unresponsiveness to 2B4 engagement, although its
surface expression is not affected. Thus, the ability of 2B4
to induce NK cell activation appears to be dependent on
the coengagement of main triggering receptors including
NKp46. This supports the notion that 2B4 may function as
a coreceptor rather than as a true receptor (23). 2B4 is a
member of the CD2 subfamily of the Ig-SF which also in-
cludes CD48, CD58, CD84, CD150 (also termed SLAM),
and CD299 (Ly9) (24). 2B4 is characterized, in its extracel-
lular portion, by a membrane-distal IgV domain and a
membrane-proximal IgC2 domain. The transmembrane
region lacks charged amino acids involved in the associa-
tion with immune tyrosine-based activating motif (ITAM)-
bearing signal transducing polypeptides (21, 22, 25–27). In-
terestingly, the cytoplasmic tail contains four tyrosine-based
motifs (TxYxxI/V) that undergo phosphorylation upon so-
dium pervanadate treatment (27, 28) or cell triggering with
anti-2B4 mAb (29). Different polypeptides have been
shown to associate with 2B4 and to participate in the 2B4-
mediated signal transduction pathway. Thus, upon tyrosine
phosphorylation, 2B4 associates with a small cytoplasmic
polypeptide termed Src homology 2 domain–containing
protein (SH2D1A; references 27 and 28) also referred as
SLAM-associated protein (SAP [30]). Controversy still ex-
ists on which of the SH2-containing phosphatases (SHP)
binds to 2B4. Although 2B4/SHP-2 association has been
described in cell transfectants (27), in normal NK cells, only
2B4/SHP-1 association could be detected (28). Recently,
it has been shown that, in normal NK cells, 2B4 constitu-
tively associates with the linker for activation of T cells
(LAT [29]). mAb-mediated cross-linking of 2B4 results in
tyrosine phosphorylation of LAT and recruitment of PLC
 
 
 
and Grb2 intracytoplasmic signaling molecules (29).
A dramatically altered function of 2B4 has recently been
detected in individuals affected by the X-linked lympho-
proliferative disease (XLP [28, 31, 32]). XLP is a severe in-
herited immune deficiency, characterized by the inability
to control EBV infection resulting in fulminant infectious
mononucleosis or lymphoma (33, 34). The genetic basis of
XLP, i.e., critical mutations in the SH2D1A encoding gene
(30, 35, 36) has been identified. Due to these mutations, in
XLP-NK cells 2B4 fails to associate with SH2D1A but as-
sociates with SHP-1 and mediates inhibitory (rather than
activating) signals (28). Thus, the engagement of 2B4 with
CD48 expressed at high densities on EBV-infected cells re-
sults in a sharp inhibition of the NK-mediated cytotoxicity.
In this study we identified NTB-A, a novel surface mol-
ecule that induces triggering of cytotoxicity in human NK
cells. Molecular characterization revealed a novel member
of the Ig-SF belonging to the CD2 subfamily. Similar to
2B4, NTB-A associates with SH2D1A in normal NK cells
while, in individuals affected by XLP, the lack of this asso-
ciation results in NTB-A–mediated inhibitory, rather than
activating, signals. This, in turn, renders XLP-NK cells un-
able to kill EBV-infected
 
 
 
target cells.
 
Materials and Methods
 
mAbs.
 
MA127 mAb was obtained by immunizing a 5-wk-
old BALB/c mouse with the NK clone KK4 (surface phenotype:
CD3
 
 
 
CD16
 
 
 
CD56
 
 
 
NCR
 
 
 
CD94/NKG2A
 
 
 
) as described pre-
viously (6, 8, 9). The following mAbs, produced in our lab, were
used in this study: JT3A (IgG2a, anti-CD3), BAB281 and KL247
(IgG1 and IgM, respectively, anti-NKp46), Z231 and KS38
(IgG1 and IgM, respectively, anti-NKp44), Z25 and F252 (IgG1
and IgM, respectively, anti-NKp30), PP35 and S39 (IgG1 and
IgG2a, respectively, anti-2B4), KD1 and c127 (IgG2a and IgG1,
respectively, anti-CD16), c218 and GPR165 (IgG1 and IgG2a,
respectively, anti-CD56), A6-136 (IgM, anti-HLA class I),
XA185 (IgG1, anti-CD94), and Z199 and Z270 (IgG2b and
IgG1, respectively, anti-NKG2A).
D1.12 (IgG2a, anti-HLA-DR) mAb was provided by Dr. R.S.
Accolla (University of Pavia, Pavia, Italy). HP2.6 (IgG2a, anti-
CD4) mAb was provided by Dr. P. Sanchez-Madrid (University
of Madrid, Madrid, Spain). WT31 (IgG1, anti–TCR-
 
 
 
/
 
 
 
) was
purchased by Becton Dickinson.
 
*
 
Abbreviations used in this paper:
 
 Ig-SF,
 
 
 
Ig superfamily; ITAM, immune ty-
rosine-based activating motif; ITIM, immune tyrosine-based inhibitory
motif; KIR, killer inhibitory receptor; LAT, linker for activation of T
cells; NCR, natural cytotoxicity receptor; RT, reverse transcription;
XLP, X-linked lymphoproliferative disease. 
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Purification of Polyclonal or Clonal NK Cell Populations.
 
To ob-
tain PBLs, PBMCs were isolated on Ficoll-Hipaque gradients and
depleted of plastic-adherent cells (6). Enriched NK cells were iso-
lated by incubating PBLs with anti-CD3 (JT3A), anti-CD4
(HP2.6), and anti–HLA-DR (D1.12) mAbs (30 min at 4
 
 
 
C) fol-
lowed by goat anti–mouse coated Dynabeads (Dynal; 30 min at
4
 
 
 
C) and immunomagnetic depletion (6). CD3
 
 
 
CD4
 
 
 
DR
 
  
 
cells
were cultured on irradiated feeder cells in the presence of 100 U/ml
rIL-2 (Proleukin; Chiron Corp.) and 1.5 ng/ml PHA (GIBCO
BRL) in order to obtain polyclonal NK cell populations or, after
limiting dilution (6, 8), NK cell clones.
 
XLP Patients.
 
The XLP patients analyzed in this study are af-
fected by mutations at the SH2D1A locus represented by: G to T
nucleotide change at the translation initiation codon (ATG to
ATT), leading to a methionine to isoleucine amino acid change
(patient A) and C to T nucleotide change at position 163, leading
to premature termination at codon 55 (patients B and C). As de-
scribed previously (28), these mutations result in a complete ab-
sence of SH2D1A protein.
 
Cytolytic Activity and Flow Cytofluorimetric Analysis.
 
NK cells
were tested for cytolytic activity against the (Fc
 
 
 
R
 
 
 
) P815 mu-
rine mastocytoma cell line or the lymphoblastoid cell line (LCL)
721.221 EBV cell line (HLA class I
 
 
 
CD48
 
 
 
Fc
 
 
 
R
 
 
 
) in a 4-h
 
51
 
Cr-release assay as described previously (6, 8, 9, 28). The con-
centrations of the various mAbs added were 0.5 
 
 
 
g/ml for redi-
rected killing or 10 
 
 
 
g/ml for masking experiments. The E/T ra-
tios are indicated in the text.
For one- or two-color cytofluorimetric analysis (FACScan™;
Becton Dickinson) cells were stained with the appropriate mAbs
followed by PE- or FITC-conjugated isotype-specific goat anti–
mouse second reagent (Southern Biotechnology Associates, Inc.
[6, 8, 9]).
 
Biochemical Characterization of NTB-A Molecules.
 
20 
 
 
 
 10
 
6
 
cells were labeled with Biotin (Pierce Chemical Co.) as described
previously (28). 1% NP-40 cells lysates were immunoprecipitated
with Sepharose-PA (Amersham Pharmacia Biotech)-coupled
mAbs. Samples were analyzed by discontinuous SDS-PAGE ei-
ther undigested or digested with N-glycosidase F (Boehringer;
reference 28) and transferred to Immobilon
 
 
 
P
 
 
 
(Millipore). After
staining with Neutravidin (Pierce Chemical Co.), the Renais-
sance Chemiluminescence Kit (NEN Life Science Products) was
used for detection.
 
Analysis of the NTB-A Signal Transduction Pathway.
 
NK cells
(10
 
8
 
) were stimulated or not with 100 
 
 
 
M sodium pervanadate
(28). 1% NP-40 or 1% digitonin cell lysates were immunoprecip-
itated with Sepharose-PA (Amersham Pharmacia Biotech)-cou-
pled mAbs. Samples were analyzed in discontinuous SDS-PAGE,
transferred to Immobilon
 
 
 
P
 
 
 
(Millipore), and probed with: (a)
anti-phosphotyrosine mAb (PY20-HRPO; Transduction Labora-
tories); (b) anti–SHP-2 or anti–SHP-1 mAbs (PTP1D and
PTP1C, respectively; Transduction Laboratories) followed by
rabbit anti–mouse-HRPO (Dako); (c) anti-SH2D1A rabbit anti-
serum (produced by Eurogentec S.A; reference 28) followed by
donkey anti–rabbit-HRPO (Amersham Pharmacia Biotech). The
Renaissance Chemiluminescence Kit (NEN Life Science Prod-
ucts) was used for detection.
Putative NTB-A association with known signal transducing
molecules was analyzed by probing NTB-A immunoprecipitates,
obtained from 1% digitonin cell lysates, with anti-Fc
 
 
 
RI
 
 
 
 (pro-
vided by E. Vivier, University de la Méditerranée, Marseille,
France), anti-DAP12 (SI-28; reference 10), and anti-LAT (UBI;
Upstate Biotechnology) antisera or with anti-CD3
 
  
 
mAb (TIA/2;
Immunotech).
 
Library Screening by cDNA Expression in COS-7 and Sib Selec-
tion.
 
The library screening was performed as described previ-
ously (7). In brief, the cDNA library, fractionated in 10 different
pools, was transiently transfected in COS-7 cells using nonliposo-
mal FuGene-6 reagent (Roche) following the manufacturer’s in-
struction. Selection of positive pools was performed by immuno-
cytochemical staining using the specific anti–NTB-A mAb
MA127 and sib selection.
 
DNA Sequencing and Reverse Transcription PCR Analysis.
 
DNA sequencing was performed using d-Rhodamine Termina-
tor Cycle Sequencing kit and a 377 ABI automatic sequencer
(PerkinElmer/Applied Biosystems
 
).
 
 The analysis of the putative
protein coded by the KALI cDNA was performed using the Gene-
Works 2.5.1N and the site http://genome.cbs.dtu.dk/htbin/
nph-webface. RNA, extracted using RNAzol (Cinna/Biotecx),
and oligo (dT)-primed cDNA were prepared from polyclonal
NK cell populations and thymocytes by standard techniques. The
set of primers KALI-up (containing the ATG initiation codon):
5
 
 
 
 GCG GAA AGC ATG TTG TGG and KALI-down (de-
signed in the 3
 
 
 
 untranslated region): 5
 
 
 
 TCA TTC CCG AAT
TCC TCT G were used to amplified the KALI-ORF. 30 cycles
PCR (30 s, 95
 
 
 
C; 30 s, 60
 
 
 
C; and 30 s, 72
 
 
 
C) was performed us-
ing TAQ-GOLD (PerkinElmer/Applied Biosystems) after preac-
tivation of 12 min at 95
 
 
 
C. The obtained amplification products
were cloned into pcDNA3.1/V5/His-TOPO vector using the
Eukaryotic-TOPO-TA Cloning kit (Invitrogen) and sequenced.
 
Transient Transfection.
 
COS-7 cells (5 
 
 
 
 10
 
5
 
/plate) were
transfected with VR1012/KALI construct using FuGene-6 re-
agent (Roche; reference 23). After 48 h, transfected cells were
stained with MA127 (anti–NTB-A) and PP35 (anti-2B4; as neg-
ative control) mAbs followed by Ig-G1 PE-conjugated goat anti–
mouse second reagent and analyzed by flow cytometry using a
FACSort™ (Becton Dickinson).
 
Chromosomal Localization and Zoo-Blot Analysis.
 
The Somatic
Cell Hybrid blot (BIOS Laboratories), containing 20 multichro-
mosomal somatic human/hamster cell hybrids plus 3 control ge-
nomic DNAs (human, hamster, and mouse) was used to assign the
KALI gene to a specific chromosome (10). The open reading
frame of KALI gene was used as probe to perform high stringency
hybridization (37). Analysis of cross-specific conservation of KALI
gene was performed using Zoo-Blot from CLONTECH Labora-
tories, Inc. This Southern blot contained genomic DNA from
human, Rhesus monkey, Sprague-Dawley rat, BALB/c mouse,
dog, cow, rabbit, chicken, and 
 
Saccharomyces cerevisiae
 
 yeast.
Washes were carried out under low stringency condition (7).
 
Results
 
Identification and Cellular Distribution of NTB-A Molecule.
 
Mice were immunized with the human NK cell clone KK4
(surface phenotype: CD3
 
 
 
CD16
 
 
 
CD56
 
  
 
NCR
 
 
 
CD94/
NKG2A
 
 
 
). After cell fusion, a mAb, termed MA127
(IgG1), was selected on the basis of its ability to induce cy-
totoxicity in polyclonal or clonal NK cells (including the
immunizing NK cell clone KK4) in a redirected killing as-
say against the Fc
 
 
 
R
 
 
 
 P815 murine target cells (see below).
The cell surface distribution of the MA127-reactive mole-
cules was analyzed by indirect immunofluorescence and
cytofluorimetric analysis in peripheral blood mononuclear
cells (PBMCs) from normal donors. As shown in Table I,
MA127 mAb brightly stained NK, T, and B lymphocytes. 
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On the other hand, no reactivity was detected with mono-
cytes, granulocytes, and a panel of nonlymphoid cell lines.
Polyclonal populations of either NK cells or TCR-
 
 
 
/
 
 
 
 
 
cells or thymocytes were surface-labeled with biotin and
cell lysates were immunoprecipitated with MA127 mAb.
In all instances, this mAb immunoprecipitated a surface
molecule of 
 
 
 
60 kD both under reducing (Fig. 1) and
nonreducing conditions (not shown). The protein back-
bone remaining after treatment with N-glycosidase F, dis-
played a molecular mass of 
 
 
 
37 kD.
These data suggested that MA127 mAb may recognize a
novel triggering molecule expressed not only by NK cells
but also by T and B lymphocytes; this molecule was there-
after termed NK-T-B-antigen (NTB-A).
 
Clonal Heterogeneity in Response to Anti–NTB-A mAb-
mediated Cross-Linking.
 
It has been shown that heteroge-
neity exists among NK cell clones in their ability to kill a
given HLA class I–negative target cell and that this reflects
the differential expression of NCRs (12). Thus, NK cell
clones displaying strong cytolytic activity express high lev-
els of NCRs (NCR
 
bright
 
) whereas those with low cytolytic
activity express low amounts of NCRs (NCR
 
dull
 
). Impor-
tantly, the NCR surface density was also found to correlate
with the function of 2B4. Thus, although 2B4 is expressed
at similar surface densities in both types of NK cell clones,
it induces cytotoxicity only by the NCR
 
bright
 
 ones (23).
 
 
 
A
panel of NK cell clones displaying either NCR
 
bright
 
 or
NCR
 
dull
 
 phenotype was analyzed in a redirected killing as-
say against P815 target cells in the presence of MA127
mAb. As shown in Fig. 2 a, whereas NKp46
 
bright
 
 clones
were responsive both to anti–NCR and anti–2B4 or anti–
NTB-A mAbs, NKp46
 
dull
 
 clones responded poorly to all of
these mAbs (although they did respond efficiently to anti-
CD16 mAb). Remarkably, all the NK cell clones analyzed
expressed similar surface densities of NTB-A (not shown).
To further explore the relationship between responsive-
ness to anti–NTB-A mAb and surface density of NKp46,
we analyzed the effect of surface modulation of NKp46
molecules. To this end, NKp46
 
bright
 
 clones were incubated
overnight in the presence of immobilized anti-NKp46
mAb (KL247, IgM). This resulted in a virtually complete
disappearance of NKp46 molecules from the cell surface
(23; data not shown). This treatment did not affect the sur-
face expression of NTB-A or of other NK cell surface mol-
ecules. NKp46-modulated clones were used as effectors in
a redirected killing assay against P815 target cells in order
to analyze their responsiveness to mAbs directed to differ-
ent surface molecules. In agreement with previous data in-
dicating that NKp46 functions as the major human recep-
tor in the recognition and lysis of murine targets (7, 12,
38), NKp46-modulated NK cells displayed a sharply re-
duced ability to spontaneously lyse P815 cells (in the ab-
sence of mAbs; Fig. 2 b; reference 23). Importantly, the
analysis of the effect of different mAbs revealed that the
unresponsiveness was limited not only to anti-NKp46 or
anti-2B4 mAbs (23) but also to anti–NTB-A mAb. On the
contrary, responses to anti-NKp44, anti-NKp30, or anti-
CD16 mAb were not affected (23).
 
Table I.
 
Surface Expression of MA127-reactive Molecules
 
Cells Histotype
MA127
mAb
Anti-2B4
mAb
Resting NK cells   
Activated NK cells   
Resting T cells     (subset)
PHA blasts      (subset)
Resting B cells   
Thymocytes   
Monocytes   
Granulocytes   
YT NK cell line   
NK.L NK cell line   
NK3.3 NK cell line   
NK92 NK cell line   
JA3 T leukemia   
H9 T leukemia   
HSB2 T leukemia   
Raji Burkitt lymphoma   
DAUDI Burkitt lymphoma   
LCL 721.221 EBV cell line   
U937 Histocytic lymphoma   
HL60 Promyelocytic leukemia   
TF1 Promyelocytic leukemia   
MM6 Promyelocytic leukemia   
Eo/A3 Eosinophilic leukemia   
MEL15392 Melanoma   
MEL501 Melanoma   
FO-1 Melanoma   
1074 mel Melanoma   
A549 Lung carcinoma   
SMMC Hepatoma   
HELA Cervical Carcinoma   
IGROV-1 Ovarian Carcinoma   
YAC-1 Murine thymoma   
BW1502 Murine thymoma   
P815 Murine mastocytoma   
COS-7 Monkey kidney fibroblast   
Normal cells and tumor cell lines of different histotype were analyzed by
immunofluorescence and FACS® analysis for reactivity with MA127
and PP35 (anti-2B4) mAbs followed by PE-conjugated goat anti–mouse
IgG1. Cells are of human origin unless otherwise specified.239 Bottino et al.
These data are reminiscent of previous data using anti-
2B4 mAbs (23) and suggest that also NTB-A may function
as a coreceptor in the mechanism of NK cell activation.
Note, however, that both the cell surface distribution and
the molecular mass of NTB-A are clearly distinct from
those of 2B4 (see Table I and Fig. 1).
Involvement of NTB-A in NK-mediated Killing of EBV 
Target Cells. 2B4 has been shown to cooperate with
NKp46 in the process of recognition and killing of EBV-
infected cells such as the (HLA class I CD48 Fc R ) LCL
721.221 (28). On the contrary, the contribution of other
triggering receptors expressed by NK cells, including
NKp30, NKp44, and NKG2D, in NK-mediated lysis of
LCL 721.221 is marginal or even absent (data not shown).
We analyzed whether also NTB-A is involved in lysis of
these target cells. Thus, NK cell clones, derived from nor-
mal donors, were assessed for cytolytic activity against the
LCL 721.221 (Fig. 2 c) or Daudi Burkitt lymphoma (not
shown) cell lines, either in the absence or in the presence of
mAbs directed to NTB-A, 2B4, or NKp46. mAb-mediated
Figure 1. Biochemical characterization of NTB-A molecules. NK cell,
TCR- /   cell and thymocyte (Thy) populations that had been surface la-
beled with biotin were immunoprecipitated (IP) with MA127 (anti–NTB-A)
or S39 (anti-2B4) mAbs. Samples were treated ( ) or not ( ) with N gly-
cosidase F and analyzed in a 9% SDS-PAGE under reducing conditions.
Z270 (anti-NKG2A) and WT31 (C ) (anti–TCR- / ), both of IgG1 iso-
type, were used as controls. Molecular weight markers (kD) are indicated.
Figure 2. Functional analysis of NTB-A molecules in redirected killing assay and in NK-mediated killing of EBV  target cells. (a) Representative
NKp46bright (MX367, CC16) and NKp46dull (HER12, HER3) NK cell clones were analyzed in a redirected killing assay against (Fc R ) P815 murine
target cells either in the absence or in the presence of mAbs specific for the indicated molecules. All the mAbs were of the IgG1 subclass. (b) The repre-
sentative NKp46bright clone (MOA110) either untreated or modulated with anti-NKp46 (KL247, IgM) mAb was tested for cytolytic activity in a redi-
rected killing assay against murine P815 target cells either in the absence or in the presence of mAbs specific for the indicated molecules. In both experi-
ments the E/T ratio used was 8:1. (c) Two representative NKp46bright NK cell clones (MX367 and MOA110) were analyzed for cytolytic activity against
the LCL 721.221 EBV cell line (HLA class I CD48 Fc R ) either in the absence or in the presence of mAbs specific for the indicated molecules. The
E/T ratio used was 2:1. (d) The NK92 NK cell line was analyzed for cytolytic activity against the (Fc R ) P815 murine target cells or the LCL 721.221
EBV cell line, either in the absence or in the presence of mAbs specific for the indicated molecules. The E/T ratio used was 5:1. The results are represen-
tative of seven independent experiments. The standard deviation of the mean of the triplicates was  4%.240 A Novel SH2D1A-associated Triggering Receptor
blocking of either NTB-A or 2B4 did not significantly af-
fect the NK-mediated killing of these targets. However,
the combined use of mAbs directed to NTB-A and 2B4 re-
sulted in a partial inhibition of lysis. Importantly, the inhib-
itory effect obtained by mAb-mediated masking of NKp46
was significantly incremented in the presence of either
anti–NTB-A or anti-2B4 mAbs and maximal inhibition
was obtained when the three molecules were simulta-
neously blocked by the respective mAbs. Isotype-matched
anti-CD56 mAb used either alone or in combination had
no inhibitory effect (not shown). These data suggest that,
in normal cells, NTB-A, together with 2B4, cooperates
with NKp46 in the induction of NK-mediated cytotoxicity
against EBV  target cells. Moreover, they suggest that
NTB-A, similar to 2B4, recognizes cell surface ligand(s)
expressed on EBV  targets. However, it should be stressed
that data obtained using normal NK cells may be of diffi-
cult interpretation because different receptors (such as
NKp46) and coreceptors (such as NTB-A and 2B4) are in-
volved in the cytolytic activity against EBV  targets. On
the other hand, that NTB-A, similar to 2B4 (28), is indeed
capable of recognizing EBV  target cells was confirmed by
experiments in which the NK92 leukemic NK cell line
was used as source of effector cells. This cell line is
NTB-A 2B4  but expresses very low amounts of NKp46
(not shown). Accordingly, mAb-mediated cross-linking of
NKp46 fails to induce NK92-mediated cytotoxicity against
P815 in a redirected killing assay (Fig. 2 d). Importantly
however, in this assay the cytotoxicity of NK92 cells could
be strongly enhanced by mAb-mediated cross-linking of
either NTB-A or 2B4. These data suggest that in the case
of NK92 cells (different from normal NK cells) the NTB-A
and 2B4-mediated activation was mostly NKp46 indepen-
dent. Thus, NK92 cell line offered a useful tool to clarify
the involvement of NTB-A in the recognition and killing
of EBV  target cells. Indeed, as shown in Fig. 2 d, NK92
cells were strongly cytolytic against LCL 721.221 target
cells. mAb-mediated masking of either NTB-A or 2B4 re-
sulted in a consistent inhibition of cytotoxicity whereas the
combined use of both mAbs resulted in the virtual abroga-
tion of NK92-mediated killing of LCL 721.221. Alto-
gether, these data support the notion that NTB-A is in-
volved in the recognition of EBV  targets.
Analysis of the NTB-A–mediated Signal Transduction Path-
way. NTB-A molecules were immunoprecipitated from
polyclonal NK cell populations treated or not with sodium
pervanadate.  Tyrosine phosphorylation of NTB-A mole-
cules was consistently detectable in immunoprecipitates ob-
tained from sodium pervanadate–treated but not from un-
treated cells (Fig. 3 a). On the contrary, NTB-A did not
associate with signal transducing polypeptides, including
CD3 , Fc RI , and DAP12 (not shown). These data sug-
gested that, different from NCRs but similar to 2B4, NTB-A
molecules may display tyrosine-based motifs in their in-
tracytoplasmic portion. These motifs were likely to mediate
the association with intracytoplasmic molecules involved in
the transduction of activating signals. To analyze this possi-
bility, NTB-A immunoprecipitates, obtained as above, were
probed with anti-SH2D1A antiserum or with mAbs specific
for SHP-1 or SHP-2. As a control, identical cell lysates were
immunoprecipitated with mAbs specific for 2B4, or for the
inhibitory receptor protein 60 (IRp60) or NKp46. 2B4 has
been shown to associate with SHP-1 and, upon sodium per-
vanadate treatment or mAb-mediated cross-linking, with
SH2D1A (27–29). On the other hand, IRp60 is an immune
tyrosine-based inhibitory motif (ITIM)-bearing receptor
that associates with both SHP-1 and SHP-2 (39), while
NKp46, lacking tyrosine-based motifs in the cytoplasmic
tail, transduces the activating signals via the association with
CD3  and Fc RI  ITAM-containing transmembrane adap-
tor molecules (4). This analysis revealed the presence of
SHP-1 in NTB-A immunoprecipitates obtained from both
Figure 3. Analysis of the NTB-A–specific signal transduction pathway. (a) Cell lysates derived from a polyclonal NK cell population either untreated
( ) or treated ( ) with sodium pervanadate (100  M, 10 min, 37 C), were sequentially immunoprecipitated (IP) with anti-2B4 and anti-NTBA mAbs.
Samples were analyzed under reducing conditions in 8% SDS-PAGE and probed with anti-phosphotyrosine (anti-P-Tyr). (b) Cell lysates derived as in
panel a were sequentially immunoprecipitated with anti-2B4, anti–NTB-A, anti-NKp46, and anti-IRp60. Equal amounts of each immunoprecipitate
were analyzed under reducing conditions in 8% SDS-PAGE and probed with either anti–SHP-1 or anti–SHP-2 mAbs. (c) Cell lysates derived as in panel
a were sequentially immunoprecipitated with anti-2B4, anti–NTB-A, and anti-SH2D1A. Samples were analyzed under reducing conditions in 14%
SDS-PAGE and probed with anti-SH2D1A antiserum. In each panel molecular weight markers (kD) are indicated.241 Bottino et al.
untreated and sodium pervanadate–treated cells. In contrast,
the association of NTB-A with SHP-2 could be detected
only in treated cells (Fig. 3 b). Notably, treatment with so-
dium pervanadate also led to the association of NTB-A with
SH2D1A molecules (Fig. 3 c).
Altogether, these data strengthened the idea that NTB-A
molecules, although exhibiting a distinct surface distribu-
tion in PBMCs, display functional and molecular character-
istics similar to 2B4.
NTB-A Mediates Inhibitory Rather than Activating Signals in
XLP-NK Cells. In view of the similarities with 2B4, we
analyzed the function of NTB-A in polyclonal and clonal
NK cells from different patients affected by XLP (see Mate-
rials and Methods). XLP-NK cells were analyzed in a redi-
rected killing assay against P815 murine targets either in the
absence or in the presence of mAbs specific for various sur-
face molecules including NTB-A and 2B4. As shown in
Fig. 4 a, and in agreement with previous data (28), in NK
cells from the representative XLP patient A, 2B4 exhibited
inhibitory rather than activating function whereas CD16
(not shown) and NCRs displayed normal triggering capa-
bility. Importantly, cross-linking of NTB-A by specific
mAb also resulted in a marked inhibition of spontaneous
cytotoxicity. An even greater inhibitory effect was ob-
served in the presence of both NTB-A– and 2B4-specific
mAbs (Fig. 4 a). Moreover, cross-linking of NTB-A was
able to inhibit the cytolytic activity induced by anti-CD16
(not shown) or anti-NCR mAbs. Consistent with previous
results (28), a similar inhibitory activity was observed in the
presence of anti-2B4 mAb. Although not shown, the ab-
sence of SH2D1A in XLP-NK cells did not affect the level
of expression of NTB-A at the cell surface.
Based on the observation that NTB-A, similar to 2B4,
may recognize cell surface ligand(s) expressed on EBV 
target cells (see above) we asked whether in XLP-NK cells
this interaction could induce the generation of inhibitory
signals via NTB-A. XLP-NK cells were further analyzed
for their ability to lyse the (HLA class I Fc R ) LCL
721.221 EBV  cell line expressing large amounts of CD48
(i.e., the natural ligand of 2B4). In agreement with previ-
ous report (28), these target cells were efficiently lysed by
normal NK cells while they were resistant to lysis by XLP-
NK cells (Fig. 4 b). mAb-mediated masking of either 2B4
(28) or NTB-A molecules resulted in partial restoration of
lysis of LCL 721.221 cells; this effect was further incre-
mented by the simultaneous masking of both molecules
(Fig. 4 b). It is of note that, unlike 2B4, NTB-A molecule
is expressed by both effectors (NK cells) and targets (B
cells). However, restoration of lysis could be detected only
upon pretreatment of effector but not of target cells with
anti–NTB-A mAb (not shown). Similar results were ob-
tained in XLP-NK cells derived from patient B (28) and
patient C carrying the same mutation (data not shown).
Thus, the lack of SH2D1A in XLP patients resulted in a
profound dysfunction not only of 2B4 but also of the
newly identified NTB-A molecule. Accordingly, both
molecules appear to contribute to the inability of XLP-NK
cells to kill EBV  target cells.
Molecular Cloning and Characterization of the cDNA Encod-
ing the NTB-A Surface Molecule. The cDNA encoding
NTB-A molecule was isolated from an NK cell–derived
cDNA expression library using MA127 mAb (7). This
cDNA (referred as KALI; sequence data available from
GenBank/EMBL/DDBJ under accession no. AJ277141)
was characterized by a length of 2,744 bp. Transfection of
the VR1012/KALI construct in COS-7 cells allowed the
surface expression of molecules that were brightly stained
by MA127 mAb (Fig. 5). Moreover, MA127 mAb specifi-
cally immunoprecipitated from cell transfectants a protein
that, after treatment with N-glycosidase F, displayed a pro-
tein backbone identical to that of NTB-A molecules de-
rived from polyclonal NK cells (not shown).
The predicted amino acid sequence is consistent with a
type I transmembrane protein of 331 amino acids belong-
ing to the Ig-SF (Fig. 6). The NTB-A molecule is charac-
terized by a 21 amino acid leader peptide preceding an ex-
Figure 4. Functional analysis of NTB-A molecules in NK cells derived
from XLP patients. (a) Polyclonal NK cell population derived from XLP
patient A was analyzed for cytolytic activity in a redirected killing assay
against the (Fc R ) P815 target cell line either in the absence or in the
presence of mAbs specific for the indicated molecules. The E/T ratio used
was 8:1. All the mAbs used in this experiment were of the IgG1 isotype.
(b) Polyclonal NK cell populations derived from XLP patient A or from a
healthy donor were analyzed for cytolytic activity against the LCL
721.221 EBV cell line (HLA class I CD48 Fc R ) either in the absence
or in the presence of mAbs specific for the indicated molecules. The E/T
ratio used was 6:1. The results are representative of six independent ex-
periments. The standard deviation of the mean of the triplicates was  5%.242 A Novel SH2D1A-associated Triggering Receptor
tracellular region of 204 residues. Protein sequence analysis
suggests that the extracellular portion is composed by a
N-terminal V-type domain (lacking the classical disulfide
bond) followed by a C2-type domain (characterized by
two possible intradomain disulfide bonds). The extracellu-
lar portion contains seven potential N-linked glycosylation
sites, but no putative O-glycosylation sites. A 23 amino
acid long transmembrane region, lacking charged amino
acid residues, precedes a relatively long (83 amino acids) in-
tracytoplasmic portion that contains three tyrosine residues.
Two tyrosine residues are part of the TxYxxV/I motif that
has recently been described in the 2B4 cytoplasmic tail
(25–28). Notably, these motifs are believed to represent
consensus sequence for the association with SH2D1A. The
third tyrosine residue is included in a classical ITIM (I/V/
L/SxYxxL/V; reference 3) that is absent in the 2B4 cyto-
plasmic tail.
Reverse transcription (RT)-PCR performed on RNA
derived from different NK cell clones using KALI ORF-
specific primers revealed the existence of a second cDNA
(termed KALIb; GenBank/EMBL/DDBJ accession no.
AJ306388) coding for a putative allelic isoform of NTB-A.
This cDNA is characterized by an extra codon (CAG) re-
sulting in the insertion of an Ala residue at position 266 of
the mature protein.
Comparison of the NTB-A amino acid sequence in
GenBank/EMBL/DDBJ database with other previously
identified proteins revealed homology with CD84 (40)
(25% of identity). Chromosomal localization by Southern
blot analysis revealed segregation of NTB-A encoding gene
on human chromosome 1 (not shown). Remarkably, the
same chromosomal localization has been established also for
all the genes coding for the various members of the CD2
subfamily (24). This finding, together with the particular
core structure of the Ig-like domains (characterized by an
N-terminal non–disulfide-bonded Ig-V domain and by a
membrane-proximal Ig-C2 domain containing two possi-
ble intradomain disulfide bonds) suggests that NTB-A rep-
resents a novel member of the CD2 subfamily. Finally, hy-
bridization of zooblot with KALI ORF probe suggested a
cross-species conservation between human and monkey
(not shown).
Discussion
In this study we have identified, molecularly character-
ized, and cloned NTB-A, a novel triggering surface mole-
cule belonging to the CD2 subfamily, that is expressed on
resting and activated lymphoid populations including NK,
T, and B lymphocytes. Similar to 2B4 (23), triggering of
normal NK cells via NTB-A requires the simultaneous en-
gagement of NKp46. The role of NTB-A as a coreceptor is
further documented by mAb-mediated masking experi-
ments. In these experiments, the lysis of EBV-infected B
cell lines mediated by normal NK cells was inhibited by the
simultaneous masking of NTB-A, NKp46, and 2B4. Bio-
chemical analysis revealed that NTB-A, similar to 2B4 (27,
28), associates with SH2D1A and SHP. SH2D1A is a small
intracytoplasmic adaptor molecule the expression of which
appears to be highly regulated. Indeed, very low levels of
SH2D1A can be detected in resting cells while they dra-
matically increase upon cell activation (41). It is unlikely
that SH2D1A may play a direct role in costimulation. On
the other hand, it is likely that SH2D1A simply participates
to the transduction of NTB-A–mediated activating signals
by competing with the intracytoplasmic phosphatases for
binding to this activating coreceptor. Along this line, previ-
ous reports showed that SH2D1A is crucial for the trans-
duction of activating signals via 2B4 (27, 28) and CD150
(42). Moreover, 2B4 tyrosine phosphorylation and associa-
tion with SH2D1A was detected not only upon sodium
pervanadate treatment but also upon 2B4 mAb-mediated
cross-linking (29), The finding that NTB-A associates
upon tyrosine phosphorylation with SH2D1A led us to in-
vestigate the function of NTB-A in individuals affected by
XLP (33, 34). XLP is characterized by critical mutations in
the SH2D1A encoding gene (30, 35, 36). XLP patients suf-
fer from a severe immunodeficiency resulting in the inabil-
ity to control EBV infections. Previous studies suggested
that SH2D1A-associated molecules may play an important
role in the failure of cytolytic cells to kill EBV-infected tar-
get cells. In this context, 2B4 molecule, which functions as
a triggering coreceptor in normal NK cells (23), has been
shown to display a profound alteration of the signaling
pathway in the case of XLP-NK cells. Thus, due to the ab-
sence of SH2D1A association, 2B4 displays an opposite
function, i.e., mediates inhibitory rather than activating sig-
Figure 5. Surface expression of NTB-A in COS-7 cells transfected
with the VR1012/KALI construct. COS-7 cells transfected with
VR1012/KALI construct were stained with MA127 (anti–NTB-A) or
PP35 (anti-2B4) mAbs followed by PE-conjugated goat anti–mouse sec-
ond reagent and analyzed by flow cytometry. White profiles indicate cells
incubated with the second reagent only.
Figure 6. Predicted amino acid sequence of NTB-A molecule. The
putative signal peptide is indicated in lower case letters and the transmem-
brane region is boxed. Tyrosine-based motifs present in the cytoplasmic
tail are underlined. The NTB-A nucleotide sequence is available from
GenBank/EMBL/DDBJ under accession no. AJ277141.243 Bottino et al.
nals. 2B4 engagement either by specific mAb or by its
natural ligand (CD48) expressed at high density in EBV-
infected cells, resulted in downregulation of XLP-NK cell–
mediated cytotoxicity. This was true both for the sponta-
neous cytolytic activity and for the NK cell triggering
induced via different activating receptors (i.e., NKp46; ref-
erence 28, and this report).
Analysis of the amplified cDNA obtained by RT-PCR
in polyclonal XLP-NK cells revealed, in all samples ana-
lyzed, that the NTB-A sequence is identical to that ob-
tained from healthy donors (not shown). Moreover, cyto-
fluorimetric analysis of XLP-NK cells showed that the
absence of SH2D1A molecule does not affect the surface
expression of NTB-A. Importantly, in XLP-NK cells
NTB-A appears to play a role similar to 2B4 (28). Indeed,
in the absence of SH2D1A, NTB-A does not transduce
triggering but rather inhibitory signals. This can easily be
appreciated in redirected killing assays in which mAb-
mediated cross-linking of NTB-A results in inhibition of
both the spontaneous and the NCR-mediated cytotoxicity
of XLP-NK cells. More importantly, similar inhibitory sig-
nals were generated when XLP-NK cells interacted with
EBV  target cells. In addition to the 2B4/CD48 interaction
(28), another inhibitory signal was generated by the interaction
between NTB-A and still unknown ligand(s) expressed on
EBV  cells. Thus, mAb-mediated blocking of NTB-A par-
tially restored the XLP-NK cell–mediated lysis of EBV 
targets while it had no effect on the lysis of different tumor
targets including melanomas, lung carcinomas, T cell lym-
phomas, and cervical carcinomas (not shown). This sug-
gests that, similar to CD48, the expression of NTB-A
ligand(s) may be restricted to certain cell types. Alterna-
tively, only some cells may express sufficient surface densi-
ties of the ligand(s) to allow signaling upon binding with
NTB-A. It is possible that NTB-A similar to CD150 (42)
may display homophilic interactions or interact with other
members of the CD2 subfamily (as in the case of CD2/
CD48, CD2/CD58, and 2B4/CD48 interactions) (21, 22,
43). Preliminary data would suggest that the ligand for
NTB-A is not represented by CD48 (i.e., the 2B4 ligand).
Thus, upon simultaneous masking of both NTB-A and
2B4, an additive effect occurs in the restoration of XLP-
NK cell–mediated lysis of EBV  target cells (see above).
Moreover, whereas only a partial restoration of NK-medi-
ated cytotoxicity occurred upon mAb-mediated masking of
CD48 on EBV  target cells, a strong increment of lysis
could be detected by the simultaneous masking of NTB-A
on XLP-NK cells (data not shown). In this study the analy-
sis of the cytolytic activity of XLP-NK cells against EBV 
targets has been mainly evaluated against HLA class
I EBV  LCL in order to avoid interference due to killer
inhibitory receptor (KIR)/HLA class I interactions. We
previously showed, in XLP patients, that the recovery of
NK-mediated cytotoxicity against autologous HLA class
I EBV  LCL cells did not occur upon mAb-mediated dis-
ruption of HLA/KIR interactions. Unlike normal donors,
in these patients, only the simultaneous mAb-mediated
masking of HLA class I and 2B4 led to reconstitution of cy-
totoxicity (28). Although not shown, similar results could
be obtained by the simultaneous masking of HLA class I
and NTB-A. Thus, unlike in normal individuals, in XLP
patients, clearance of HLA-deficient EBV-infected cells
would be impaired because of the occurrence of inhibitory
rather than activating interactions between 2B4, NTB-A,
and their ligands. In this context, different studies reported
that downregulation of HLA class I molecules occurs dur-
ing EBV infection (44–46). However, this event may occur
“in vivo” only at given stages of EBV infection and/or it
may affect one or few HLA class I alleles. Indeed, although
most EBV-infected cells may be HLA class I  when ana-
lyzed with mAbs directed to framework determinants of
HLA class I, this analysis is clearly inadequate to reveal a
single allelic loss. It should be stressed that downregulation
of a single allele renders target cells susceptible to NK cells
expressing KIR specific for the missing allele (1).
In other reports no inhibitory function of 2B4 has been
observed in XLP-NK cells. These studies suggested a “lack
of function” of 2B4 (31, 32). Further studies should clarify
these divergent results and in particular whether they re-
flect a heterogeneity of the patients phenotype or other yet
unknown mechanisms. We are presently investigating
three additional XLP patients carrying mutations at the
SH2D1A locus different from those detected in patients A,
B, and C. Preliminary data suggest that also in these pa-
tients both 2B4 and NTB-A display inhibitory functions
(data not shown). Thus, in six different XLP patients we
could obtain consistent results. These findings may be of
particular relevance, as disruption of the interaction be-
tween 2B4 or NTB-A with their ligands may lead to resto-
ration of cytolytic function. This may have important
implications for therapy of otherwise fatal acute EBV infec-
tions in XLP patients.
As suggested by the analysis of T cell mediated cytolytic
activity in a redirected killing assay, NTB-A fails to trigger
cytotoxicity in these cells (data not shown). Also, this find-
ing is reminiscent of previous data on 2B4 molecules (28).
Notably, T cells do not express the NKp46 receptor spe-
cific for ligand(s) present on murine cells such as the P815
target cell used in redirected killing assays. Thus, CTLs may
be unresponsive to mAbs specific for 2B4 and NTB-A in
this experimental setting, simply because both molecules
act as coreceptors and require for their function a costimu-
lus provided by a true receptor (e.g., NKp46). On the
other hand, it is conceivable that, in T cells, other trigger-
ing receptors may be physiologically involved in providing
the signal required for 2B4- and NTB-A signaling. Along
this line, further studies should clarify whether EBV-spe-
cific CTLs actually use 2B4 and NTB-A as coreceptors and
whether these molecules may inhibit T cell–mediated re-
sponses against EBV in XLP patients. Regarding the func-
tion of NTB-A in B lymphocytes, studies are in progress in
order to clarify this issue. It is of note that so far no
SH2D1A could be detected in normal B cells as well as in
most B cell lines (41). Thus, it is likely that, in order to
transduce signals in B cells, NTB-A may require association
with a distinct intracytoplasmic adaptor molecule. In this244 A Novel SH2D1A-associated Triggering Receptor
context, a possible candidate is represented by the recently
described EAT-2 molecule that is expressed in B cells and
displays high identity with SH2D1A (41).
Molecular cloning revealed that NTB-A represents a
novel member of the CD2 subfamily (24). Although these
molecules display a relatively limited amino acid identity,
they are clustered on human chromosome 1 and display a
remarkably similar core structure of the Ig-like domains.
NTB-A does not contain classical ITAM consensus se-
quence in the cytoplasmic tail. Different from various acti-
vating surface receptors  but similar to 2B4 (8–10, 16),
NTB-A does not associate with DAP12, CD3 , and
Fc RI  signal transducing polypeptides. Moreover, unlike
2B4 (29), NTB-A does not associate with the LAT (not
shown). In this context, sequence analysis revealed that
NTB-A lacks both the charged amino acid residues in the
transmembrane region and the CxC/  motif (i.e., a CxC
sequence surrounded by positive-charged residues) in the
transmembrane/cytoplasmic portion. These motifs have
been suggested to play a crucial role in the different recep-
tor/adaptor interactions (4, 47). An additional feature com-
mon to 2B4 (28) is the ability of NTB-A to bind SHP-1
and, upon tyrosine phosphorylation, also SH2D1A. Con-
sistent with the latter association, the cytoplasmic tail of
NTB-A contains two TxYxxV/I motifs that are thought to
represent consensus sequences for the association with
SH2D1A (4). Moreover, the amount of SHP-1 associated
to NTB-A appears to be reduced upon sodium pervanadate
treatment and SH2D1A binding (see Fig. 3). These data are
similar to those obtained on 2B4 (28) and suggest that
SH2D1A may compete for binding to SHP-1 also in the
case of NTB-A. At variance with 2B4, NTB-A is charac-
terized by a classical ITIM motif in the cytoplasmic portion
and can associate with SHP-2 upon tyrosine phosphoryla-
tion. SHP-2 has been found to associate with both inhibi-
tory and activating receptors (48), suggesting that the final
functional outcome of the recruitment of SHP-2 may de-
pend on the functional characteristics of the different SHP-
2–specific substrates. Thus, so far, the actual role of this
phosphatase in the NTB-A–mediated signaling remains to
be determined.
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